» Articles » PMID: 21855303

Expression of Ornithine Decarboxylase During the Transport of Saquinavir Across the Blood-brain Barrier Using Composite Polymeric Nanocarriers Under an Electromagnetic Field

Overview
Publisher Elsevier
Specialty Chemistry
Date 2011 Aug 23
PMID 21855303
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

The expression of human ornithine decarboxylase (ODC) and permeability of saquinavir (SQV) across the blood-brain barrier were studied using nanoparticles (NPs) composed of poly(lactide-co-glycolide) (PLGA), poly-(γ-glutamic acid) (γ-PGA), and polyethyleneimine (PEI). SQV was encapsulated in the particle core to traverse a monolayer of human brain-microvascular endothelial cells (HBMECs) with the regulation of human astrocytes under an electromagnetic field (EMF). An increase in the weight percentage of PEI enhanced the particle size, zeta potential, and permeability of SQV. However, the viability of HBMECs reduced when the weight percentage of PEI increased. In addition, an increment in the molecular weight of γ-PGA enhanced the particle size and viability of HBMECs, and reduced the zeta potential. The permeability of SQV and expression of ODC were in the order: an EMF with amplitude modulation (AM)>an EMF with frequency modulation>no EMF. At 0.04% PEI, the AM EMF increased 2.38 times the uptake of NPs and 2.72 times the expression of ODC. The combination of PEI/γ-PGA/PLGA NPs and EMF can be an innovative strategy for delivering SQV into the brain.

Citing Articles

Passing of Nanocarriers across the Histohematic Barriers: Current Approaches for Tumor Theranostics.

Gareev K, Tagaeva R, Bobkov D, Yudintceva N, Goncharova D, Combs S Nanomaterials (Basel). 2023; 13(7).

PMID: 37049234 PMC: 10096980. DOI: 10.3390/nano13071140.


Harnessing nanostructured systems for improved treatment and prevention of HIV disease.

Monroe M, Flexner C, Cui H Bioeng Transl Med. 2018; 3(2):102-123.

PMID: 30065966 PMC: 6063869. DOI: 10.1002/btm2.10096.


Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.

Shao J, Kraft J, Li B, Yu J, Freeling J, Koehn J Nanomedicine (Lond). 2016; 11(5):545-64.

PMID: 26892323 PMC: 4910949. DOI: 10.2217/nnm.16.1.


Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis.

Chaowanachan T, Krogstad E, Ball C, Woodrow K PLoS One. 2013; 8(4):e61416.

PMID: 23630586 PMC: 3632578. DOI: 10.1371/journal.pone.0061416.